Proliferative effect of Apidra^® (insulin glulisine), a rapid-acting insulin analogue on mammary epithelial cells

References

• Becker RH. (2007). Insulin glulisine complementing basal insulins: a review of structure and activity. Diabetes Technol Ther 9:109–21.
   PubMed Web of Science ®Google Scholar
• Belfiore A, Frasca F. (2008). IGF and insulin receptor signaling in breast cancer. J Mammary Gland Biol Neoplasia 13:381–406.
   PubMed Web of Science ®Google Scholar
• Blundell T, Dodson GG, Cutfield JM, Cutfield SM. (1972). Insulin: the structure in the crystal and its reflection in chemistry and biology. Adv Protein Chem 26:279–402.
   Google Scholar
• Brange J, Volund A. (1999). Insulin analogs with improved pharmacokinetic profiles. Adv Drug Deliv Rev 35:307–35.
   PubMed Web of Science ®Google Scholar
• Brooks SC, Locke ER, Soule HD. (1973). Estrogen receptor in a human cell line (MCF-7) from breast carcinoma. J Biol Chem 248:6251–3.
   PubMed Web of Science ®Google Scholar
• Dideriksen LH, Jorgensen LN, Drejer K. (1992). Carcinogenic effect on female rats after 12 months administration of the insulin B10ASP. Abstract. Diabetes 41:143A.
   Google Scholar
• Dufourny B, Alblas J, van Teeffelen HA, van Schaik FM, van der Burg B, Steenbergh PH, Sussenbach JS. (1997). Mitogenic signaling of insulin-like growth factor I in MCF-7 human breast cancer cells requires phosphatidylinositol 3-kinase and is independent of mitogen-activated protein kinase. J Biol Chem 272:31163–71.
   PubMed Web of Science ®Google Scholar
• Frasca F, Pandini G, Sciacca L, Pezzino V, Squatrito S, Belfiore A, Vigneri R. (2008). The role of insulin receptors and IGF-I receptors in cancer and other diseases. Arch Physiol Biochem 114:23–37.
   PubMedGoogle Scholar
• Gammeltoft S, Hansen BF, Dideriksen L, Lindholm A, Schaffer L, Trub T, Dayan A, Kurtzhals P. (1999). Insulin aspart: a novel rapid-acting human insulin analogue. Expert Opin Investig Drugs 8:1431–42.
   PubMedGoogle Scholar
• Grisouard J, Medunjanin S, Hermani A, Shukla A, Mayer D. (2007). Glycogen synthase kinase-3 protects estrogen receptor-α from proteasomal degradation and is required for full transcriptional activity of the receptor. Mol Endocrinol 21:2427–39.
   PubMed Web of Science ®Google Scholar
• Hansen BF, Danielsen GM, Drejer K, Sørensen AR, Wiberg FC, Klein HH, Lundemose AG. (1996). Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency. Biochem J 315:271–9.
   PubMed Web of Science ®Google Scholar
• Hennige AM, Strack V, Metzinger E, Seipke G, Häring HU, Kellerer M. (2005). Effects of new insulin analogues HMR1964 (insulin glulisine) and HMR1423 on insulin receptors. Diabetologia 48:1891–7.
   PubMed Web of Science ®Google Scholar
• Jhun BH, Meinkoth JL, Leitner JW, Draznin B, Olefsky JM. (1994). Insulin and insulin-like growth factor-I signal transduction requires p21ras. J Biol Chem 269:5699–704.
   PubMed Web of Science ®Google Scholar
• Knowles BB, Howe CC, Aden DP. (1980). Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science 209:497–9.
   PubMed Web of Science ®Google Scholar
• Kurtzhals P, Schäffer L, Sorensen A, Kristensen C, Jonassen I, Schmid C, Trüb T. (2000). Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49:999–1005.
   PubMed Web of Science ®Google Scholar
• Liefvendahl E, Arnqvist HJ. (2008). Mitogenic effect of the insulin analogue glargine in malignant cells in comparison with insulin and IGF-I. Horm Metab Res 40:369–74.
   PubMed Web of Science ®Google Scholar
• Lu K, Campisi J. (1992). Ras proteins are essential and selective for the action of insulin-like growth factor 1 late in the G1 phase of the cell cycle in BALB/c murine fibroblasts. Proc Natl Acad Sci USA 89:3889–93.
   PubMed Web of Science ®Google Scholar
• Mathupala SP, Rempel A, Pedersen PL. (1997). Aberrant glycolytic metabolism of cancer cells: a remarkable coordination of genetic, transcriptional, post–translational, and mutational events that lead to a critical role for type II hexokinase. J Bioenerg Biomembr 9:339–43.
   Google Scholar
• Mayer D, Shukla A, Enzmann H. (2008). Proliferative effects of insulin analogues on mammary epithelial cells. Arch Physiol Biochem 114:38–44.
   PubMedGoogle Scholar
• Medunjanin S, Hermani A, De Servi B, Grisouard J, Rincke G, Mayer D. (2005). Glycogen synthase kinase-3 interacts with and phosphorylates estrogen receptor-α and is involved in the regulation of receptor activity. J Biol Chem 280:33006–14.
   PubMed Web of Science ®Google Scholar
• Mehta RG, Hawthorne ME, Steele VE. (1997). Induction and prevention of carcinogen-induced precancerous lesions in mouse mammary gland organ culture. Meth Cell Sci 19:19–24.
   Google Scholar
• Niemeyer H, Ureta T, Clark-Turri L. (1975). Adaptive character of liver glucokinase. Mol Cell Biochem 6:109–126.
   PubMed Web of Science ®Google Scholar
• Pollak MN, Schernhammer ES, Hankinson SE. (2004). Insulin-like growth factors and neoplasia. Nat Rev Cancer 4:505–518.
   PubMed Web of Science ®Google Scholar
• Rakatzi I, Ramrath S, Ledwig D, Dransfeld O, Bartels T, Seipke G, Eckel J. (2003). A novel insulin analog with unique properties: LysB3,GluB29 insulin induces prominent activation of insulin receptor substrate 2, but marginal phosphorylation of insulin receptor substrate 1. Diabetes 52:2227–38.
   PubMed Web of Science ®Google Scholar
• Rempel A, Bannasch P, Mayer D. (1994a). Microheterogeneity of cytosolic and membrane-bound hexokinase II in Morris hepatoma 3924A. Biochem J 303:269–74.
   PubMed Web of Science ®Google Scholar
• Rempel A, Bannasch P, Mayer D. (1994b). Differences in expression and intracellular distribution of hexokinase isoenzymes in rat liver cells of different transformation stages. Biochim Biophys Acta 1219:660–8.
   PubMed Web of Science ®Google Scholar
• Reynolds NA, Wagstaff AJ. (2004). Insulin aspart: a review of its use in the management of type 1 or 2 diabetes mellitus. Drugs 64:1957–74.
   PubMed Web of Science ®Google Scholar
• Schnarr B, Strunz K, Ohsam J, Benner A, Wacker J, Mayer D. (2000). Downregulation of insulin-like growth factor-1 receptor and insulin receptor substrate-1 in advanced human breast cancer. Int J Cancer (Pred Oncol). 89:506–13.
   PubMed Web of Science ®Google Scholar
• Shukla A, Grisouard J, Ehemann V, Hermani A, Enzmann H, Mayer D. (2009). Analysis of signaling pathways related to cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines. Endocr Relat Cancer 16:429–41.
   Google Scholar
• Shymko RM, Dumont E, De Meyts P, Dumont JE. (1999). Timing-dependence of insulin-receptor mitogenic versus metabolic signalling: a plausible model based on coincidence of hormone and effector binding. Biochem J 339:675–83.
   PubMed Web of Science ®Google Scholar
• Slieker LJ, Brooke GS, DiMarchi RD, Flora DB, Green LK, Hoffmann JA, Long HB, Fan L, Shields JE, Sundell KL, et al. (1997). Modifications in the B10 and B26–30 regions of the B chain of human insulin alter affinity for the human IGF-I receptor more than for the insulin receptor. Diabetologia 40 (Suppl 2):S54–61.
   PubMed Web of Science ®Google Scholar
• Soule HD, Maloney TM, Wolman SR, Peterson Jr WD, Brenz R, McGrath CM, Russo J, Pauley RJ, Jones RF, Brooks SC. (1990). Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res 50:6075–86.
   PubMed Web of Science ®Google Scholar
• Stammberger I. (2006). Insuline glulisine – A comprehensive preclinical evaluation. Int J Toxicol 25:24–33.
   Google Scholar
• Vajo Z, Duckworth WC. (2000). Genetically engineered insulin analogs: diabetes in the new millennium. Pharmacol Rev 52:1–9.
   PubMed Web of Science ®Google Scholar
• Wilde MI, McTavish D. (1997). Insulin lispro: a review of its pharmacological properties and therapeutic use in the management of diabetes mellitus. Drugs 54:597–614.
   PubMed Web of Science ®Google Scholar